bioMérieux S.A. (OTCMKTS:BMXMF - Get Free Report)'s stock price reached a new 52-week high on Tuesday . The company traded as high as $142.41 and last traded at $142.41, with a volume of 34 shares changing hands. The stock had previously closed at $136.00.
Analyst Ratings Changes
Separately, Royal Bank of Canada downgraded bioMérieux from a "moderate buy" rating to a "hold" rating in a research report on Wednesday, May 7th.
Read Our Latest Stock Report on BMXMF
bioMérieux Stock Up 0.7%
The business has a 50-day moving average price of $130.14 and a two-hundred day moving average price of $119.95. The company has a current ratio of 2.21, a quick ratio of 1.20 and a debt-to-equity ratio of 0.10.
About bioMérieux
(
Get Free Report)
bioMérieux SA develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries.
Featured Articles
Before you consider bioMérieux, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and bioMérieux wasn't on the list.
While bioMérieux currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
